STOCK TITAN

[Form 4] VOLITIONRX LTD Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4

VolitionRx Ltd (VNRX) President & CEO Cameron John Reynolds, also a director, reported buying 110,000 common shares at $0.51 each and acquiring 110,000 warrants for $0.01 apiece, in connection with an underwritten public offering that closed on October 14, 2025.

The warrants are exercisable at $0.60 and expire on October 14, 2030. Following these transactions, he directly owns 2,534,847 common shares, with additional indirect holdings of 1,007,718 shares via Concord International, Inc. and 34,076 shares held by his spouse.

VolitionRx Ltd (VNRX) il presidente e CEO Cameron John Reynolds, anche direttore, ha riferito di aver acquistato 110.000 azioni ordinarie a $0,51 ciascuna e di aver ottenuto 110.000 warrant per $0,01 ciascuno, in relazione a un'offerta pubblica sottoscritta che si è chiusa il 14 ottobre 2025.

I warrant possono essere esercitati a $0,60 e scadono il 14 ottobre 2030. A seguito di tali operazioni, possiede direttamente 2.534.847 azioni ordinarie, con ulteriori partecipazioni indirette di 1.007.718 azioni tramite Concord International, Inc. e 34.076 azioni detenute dal coniuge.

VolitionRx Ltd (VNRX) el presidente y director ejecutivo Cameron John Reynolds, además de director, informó haber comprado 110.000 acciones comunes a $0,51 cada una y haber adquirido 110.000 warrants por $0,01 cada uno, en relación con una oferta pública suscrita que cerró el 14 de octubre de 2025.

Los warrants son exercibles a $0,60 y vencen el 14 de octubre de 2030. Tras estas operaciones, posee directamente 2.534.847 acciones comunes, con participaciones indirectas adicionales de 1.007.718 acciones a través de Concord International, Inc. y 34.076 acciones en poder de su esposa.

VolitionRx Ltd (VNRX)의 사장 겸 최고경영자 카메룬 존 레이놀즈(Cameron John Reynolds), 또한 이사인 그는 일반 주식 110,000주$0.51에 매입하고 110,000주의 워런트를 $0.01씩 취득했다고 보고했습니다. 이는 2025년 10월 14일에 마감된 보증공모와 관련이 있습니다.

워런트의 권리는 $0.60에 행사할 수 있으며 만료일은 2030년 10월 14일입니다. 이 거래 후 그는 직접 일반 주식 2,534,847주를 보유하고 있으며 콘코드 인터내셔널, Inc.를 통해 1,007,718주의 간접 보유와 배우자 소유의 34,076주가 추가로 있습니다.

VolitionRx Ltd (VNRX) le président-directeur général Cameron John Reynolds, également administrateur, a annoncé avoir acheté 110 000 actions ordinaires à $0,51 chacune et acquis 110 000 warrants à $0,01 chacun, dans le cadre d'une offre publique souscrite qui a été clôturée le 14 octobre 2025.

Les warrants sont exerçables à $0,60 et expireront le 14 octobre 2030. À la suite de ces transactions, il détient directement 2 534 847 actions ordinaires, avec des participations indirectes supplémentaires de 1 007 718 actions via Concord International, Inc. et 34 076 actions détenues par son conjoint.

VolitionRx Ltd (VNRX) Präsident und CEO Cameron John Reynolds, außerdem Director, meldete den Kauf von 110.000 Stammaktien zu je $0,51 und den Erwerb von 110.000 Warrants zu je $0,01, im Zusammenhang mit einer von unternehmung unterstützten öffentlichen Übernahme, die am 14. Oktober 2025 abgeschlossen wurde.

Die Warrants sind zu $0,60 ausübbar und laufen am 14. Oktober 2030 ab. Nach diesen Transaktionen besitzt er direkt 2.534.847 Stammaktien und zusätzlich indirekt 1.007.718 Aktien über Concord International, Inc. sowie 34.076 Aktien im Besitz seines Ehepartners.

VolitionRx Ltd (VNRX) رئيس مجلس الإدارة والمدير التنفيذي كاميرون جون رينولدز، وهو أيضًا عضو مجلس إدارة، أفاد بشراء 110,000 سهماً عاديًا بسعر $0.51 لكل سهماً، وشراء 110,000 وارنٹس بسعر $0.01 للواحد، في إطار عرض عام مضمّن اكتمل في 14 أكتوبر 2025.

يمكن ممارسة Warrants بسعر $0.60 وتنتهي صلاحيتها في 14 أكتوبر 2030. عقب هذه المعاملات، يملك مباشرة 2,534,847 سهماً عاديًا، مع حيازات غير مباشرة إضافية قدرها 1,007,718 سهم عبر Concord International, Inc. و 34,076 سهم يمتلكها زوجته.

VolitionRx Ltd (VNRX) 总裁兼首席执行官 Cameron John Reynolds(也是董事)报告在一次承销的公开发售中购买了110,000股普通股,价格为$0.51美元/股,并获得了110,000份认股权证,每份价格为$0.01美元,发售于2025年10月14日日完成。

这些认股权证的行权价为$0.60,到期日为2030年10月14日。完成这些交易后,他直接持有2,534,847股普通股,并通过 Concord International, Inc. 间接持有1,007,718股,其配偶则持有34,076股

Positive
  • None.
Negative
  • None.

VolitionRx Ltd (VNRX) il presidente e CEO Cameron John Reynolds, anche direttore, ha riferito di aver acquistato 110.000 azioni ordinarie a $0,51 ciascuna e di aver ottenuto 110.000 warrant per $0,01 ciascuno, in relazione a un'offerta pubblica sottoscritta che si è chiusa il 14 ottobre 2025.

I warrant possono essere esercitati a $0,60 e scadono il 14 ottobre 2030. A seguito di tali operazioni, possiede direttamente 2.534.847 azioni ordinarie, con ulteriori partecipazioni indirette di 1.007.718 azioni tramite Concord International, Inc. e 34.076 azioni detenute dal coniuge.

VolitionRx Ltd (VNRX) el presidente y director ejecutivo Cameron John Reynolds, además de director, informó haber comprado 110.000 acciones comunes a $0,51 cada una y haber adquirido 110.000 warrants por $0,01 cada uno, en relación con una oferta pública suscrita que cerró el 14 de octubre de 2025.

Los warrants son exercibles a $0,60 y vencen el 14 de octubre de 2030. Tras estas operaciones, posee directamente 2.534.847 acciones comunes, con participaciones indirectas adicionales de 1.007.718 acciones a través de Concord International, Inc. y 34.076 acciones en poder de su esposa.

VolitionRx Ltd (VNRX)의 사장 겸 최고경영자 카메룬 존 레이놀즈(Cameron John Reynolds), 또한 이사인 그는 일반 주식 110,000주$0.51에 매입하고 110,000주의 워런트를 $0.01씩 취득했다고 보고했습니다. 이는 2025년 10월 14일에 마감된 보증공모와 관련이 있습니다.

워런트의 권리는 $0.60에 행사할 수 있으며 만료일은 2030년 10월 14일입니다. 이 거래 후 그는 직접 일반 주식 2,534,847주를 보유하고 있으며 콘코드 인터내셔널, Inc.를 통해 1,007,718주의 간접 보유와 배우자 소유의 34,076주가 추가로 있습니다.

VolitionRx Ltd (VNRX) le président-directeur général Cameron John Reynolds, également administrateur, a annoncé avoir acheté 110 000 actions ordinaires à $0,51 chacune et acquis 110 000 warrants à $0,01 chacun, dans le cadre d'une offre publique souscrite qui a été clôturée le 14 octobre 2025.

Les warrants sont exerçables à $0,60 et expireront le 14 octobre 2030. À la suite de ces transactions, il détient directement 2 534 847 actions ordinaires, avec des participations indirectes supplémentaires de 1 007 718 actions via Concord International, Inc. et 34 076 actions détenues par son conjoint.

VolitionRx Ltd (VNRX) Präsident und CEO Cameron John Reynolds, außerdem Director, meldete den Kauf von 110.000 Stammaktien zu je $0,51 und den Erwerb von 110.000 Warrants zu je $0,01, im Zusammenhang mit einer von unternehmung unterstützten öffentlichen Übernahme, die am 14. Oktober 2025 abgeschlossen wurde.

Die Warrants sind zu $0,60 ausübbar und laufen am 14. Oktober 2030 ab. Nach diesen Transaktionen besitzt er direkt 2.534.847 Stammaktien und zusätzlich indirekt 1.007.718 Aktien über Concord International, Inc. sowie 34.076 Aktien im Besitz seines Ehepartners.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Reynolds Cameron John

(Last) (First) (Middle)
1489 WEST WARM SPRINGS ROAD
SUITE 110

(Street)
HENDERSON NV 89014

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VOLITIONRX LTD [ VNRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/14/2025 P 110,000(1) A $0.51 2,534,847 D
Common Stock 1,007,718 I By Concord International, Inc.(2)
Common Stock 34,076 I By Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant (Right to Buy) $0.6 10/14/2025 P 110,000(1) 10/14/2025 10/14/2030 Common Stock 110,000 $0.01 110,000 D
Explanation of Responses:
1. The shares of common stock and accompanying common stock warrants were purchased by the reporting person from the underwriter in connection with an underwritten public offering by the Issuer. The offering closed on October 14, 2025. The reported sale price reflects the price of $0.52 per share of common stock and accompanying warrant to purchase one additional share of common stock, of which $0.01 of the sale price was allocated to the warrant.
2. The shares of common stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc.
Remarks:
/s/ Cameron John Reynolds 10/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Volitionrx

NYSE:VNRX

VNRX Rankings

VNRX Latest News

VNRX Latest SEC Filings

VNRX Stock Data

52.42M
86.79M
17.84%
22.29%
0.28%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States
HENDERSON